SMi Group's Ophthalmic Drugs 2018 conference returns to London this November

1. PLUS TWO INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPS
Wednesday, 28th November, Copthorne Tara Hotel, London, United Kingdom
B: Are Eye Drops the Best Route for Ophthalmic Therapy?
13.30 - 16.50
Workshop Leaders:
Sunil Shah, Professor, Aston University
Afzal Mohammed, Professor, Aston University
A: Practical Applications of Artificial Intelligence
in Drug Discovery, Development and Clinical Trials
08.30 - 12.30
Workshop Leader:
Andrew Radin, CEO, twoXAR
www.ophthalmicdrugs.com
Register online or fax your registration to
+44 (0) 870 9090 712 or call +44 (0) 870 9090 711
SMi Pharma
@SMiPharm
#ophdrugs
CHAIRS FOR 2018:
Mitchell de Long, Vice President, Chemistry,
Aerie Pharmaceuticals
Naj Sharif, Executive Director and Head, Global
Alliances & External Research, Santen Inc.
KEY SPEAKERS INCLUDE:
Majid Anderesi, Associate Group Clinical Director,
Ophthalmology, Roche
Caroline Barelle, CEO,
Elasmogen Ltd.
Victor Chong, Global Head of Ophthalmology,
Boehringer Ingelheim
Daniel Chung, Clinical Ophthalmic Lead,
Spark Therapeutics
Aniz Girach, Chief Medical Officer,
Nightstar Therapeutics
Peter Morgan-Warren, Medical Assessor, Licensing
Division, MHRA
David Silverman, Clinical Director, Ophthalmology,
Roche
HIGHLIGHTS IN 2018:
• Discover recent advances in the treatment of glaucoma
• Gain insight into the first FDA-approved gene therapy,
developed for the treatment of inherited retinal
dystrophy
• Discuss case studies on novel non-invasive and site-
specific drug delivery strategies
• Examine the applications of artificial intelligence in drug
discovery
• Explore the use of biomarkers and surrogate end-points
from a regulatory perspective
Sponsored by
REGISTER BY JUNE 29TH TO SAVE £300
REGISTER BY SEPTEMBER 28TH TO SAVE £200
REGISTER BY OCTOBER 31ST TO SAVE £100
Ophthalmic Drugs
Exploring the future through ocular gene editing
and strategic drug delivery
COPTHORNE TARA HOTEL, LONDON, UK
CONFERENCE:
26TH - 27TH
WORKSHOPS:
28TH
NOV
2018
SMi Presents the 2nd Annual Conference...

2. 08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks
Naj Sharif, Executive Director in R&D, Head, Global Alliances
& External Research, Santen Inc, USA
ADVANCEMENTS IN TREATMENT OF OCULAR DISEASE
OPENING ADDRESS
09.10 New strategies for treating retinal vascular diseases
• Overview for pathogenesis of ischaemic retinopathies
• Cellular and molecular mechanisms of diseases
• Targeting new pathways
• Positioning preclinical evidence in the clinical setting to aid
translation
• Conclusions and future directions
Alan Stitt, Dean of Innovation and Impact,
Queen’s University Belfast
09.50 Gene delivery & gene editing in the retina
• Overview of methods for “in vivo” delivery to the retina
• Gene delivery to different cell types in the retina
• Crispr/Cas9 mediated gene editing in the retina
Abraham Scaria, Vice President and Head, Ophthalmology,
Casebia Therapeutics
10.30 New horizon for treatment of inherited retinal dystrophy
• Voretigene: The first gene therapy approved in
ophthalmology
• Other up-coming gene therapy trials in the pipeline
• Market access difficulties for gene therapy
Dr. Daniel Chung, Clinical Ophthalmic Lead,
Spark Therapeutics
11.10 Morning Coffee
KEYNOTE ADDRESS:
11.40 Current unmet needs for geographic atrophy; where are we
now and where should we go?
• Current unmet needs for Geographic Atrophy
• Is Complement pathway the right place to go?
• What about neuroprotection?
• Is choroidal more important than the RPE in GA?
Victor Chong, Head of Ophthalmology, Boehringer Ingelheim
12.20 Genetically defined therapies in dry AMD
• Role of genetics in dry AMD
• Gyroscopes approach to the treatment of dry AMD
• Optimized drug delivery
Soraya Bekkali, CEO, Gyroscope Therapeutics
13.00 Networking Lunch
NOVEL APPROACHES TO DELIVERY OF OCULAR DRUGS
14.10 The future of ophthalmic delivery: preservative-free and
connected devices
• Understand the importance of patients’ adherence and
the cause of the poor adherence today
• Improve patients’ adherence by providing an easy to use,
convenient and ergonomic system
• Answer patients’ unmet needs by adding electronic
guidance and connectivity
Fanny Sellier, Global Category Manager for Ophthalmic
Devices, Nemera
KEYNOTE ADDRESS:
14.50 Drug delivery strategies for retinal diseases
• Drug delivery to the posterior ocular segment: Challenges
• Diseases affecting the posterior segment
• Conventional versus novel routes for the drug delivery to
the posterior segment
• Conclusion
Majid Anderesi, Associate Group Clinical Director,
Ophthalmology, Roche
15.30 Afternoon Tea
16.00 Non-invasive drug delivery technology (EvoluteTM) for
anterior segment ocular disease
• Overview of non-invasive drug delivery technology for
anterior segment ocular disease
• Results of a Phase II trial with nepafenac for post-surgical
pain and inflammation
Bob Butchofsky, CEO, Mati Therapeutics
16.40 soloMERs™ - site-specific biologics for ocular disease
• Advantages of soloMERs
• Isolation and characterisation of target specific soloMERs
• Efficacy in pre-clinical models of disease
• Elasmogen’s ocular portfolio
Caroline Barelle, CEO, Elasmogen Ltd
17.20 Chairman’s Closing Remarks and Close of Day One
Ophthalmic Drugs
Day One | Monday 26th November 2018 www.ophthalmicdrugs.com
Register online at www.ophthalmicdrugs.com
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime
networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry.
Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call:
Alia Malick, Director on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
Sponsored by
Experimentica Ltd. is a Finland-based contract research organisation (CRO) dedicated to
developing and offering preclinical ocular models and services to clients in the pharmaceutical,
biotech and academic sectors. Founded in 2013 Experimentica Ltd. offers exclusively
in-house expertise and an industry-leading portfolio of functional assays and in vivo imaging
for preclinical ocular models. The mission of Experimentica Ltd. is to bridge a gap between
the development of novel ocular models and their use in developing clinical applications.
www.experimentica.com
Nemera is a world leader in the design, development and manufacturing of drug delivery
devices for the pharmaceutical, biotechnology and generics industries. Nemera’s services and
products cover several key delivery routes: Ophthalmic, Parenteral, Nasal, Buccal, Auricular,
Pulmonary, Dermal and Transdermal. Nemera always puts patients first, providing the most
comprehensive range of devices in the industry, including off-the-shelf innovative systems,
customized design development and contract manufacturing. In particular, we provide millions
of multidose eye droppers for preservative-free formulations. www.nemera.net
Leading Media Partners:

3. 08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks
Mitchell de Long, Vice President, Chemistry,
Aerie Pharmaceuticals
ADVANCEMENTS IN THE TREATMENT OF GLAUCOMA
OPENING ADDRESS
09.10 Glaucoma / retinoprotection treatments
• Recently approved & novel drugs in view
• Novel devices to lower & control IOP
• A case for & pathways to retinoprotection
Naj Sharif, Executive Director and Head, Global Alliances
& External Research, Santen Inc, USA
KEYNOTE ADDRESS:
09.50 The discovery and SAR of netarsudil, the first FDA-approved
ROCK inhibitor for the treatment of glaucoma
• Need for new glaucoma medications after a period of
focus on surgical treatment options
• First FDA-approved ROCK inhibitor for the treatment of
glaucoma
• Future of the glaucoma landscape and back-of-the-eye
disease
Mitchell de Long, Vice President, Chemistry,
Aerie Pharmaceuticals
10.30 Morning Coffee
11.00 Standardization and validation of functional read-outs in
preclinical ocular models
• Requirement for validated reference compounds for in vivo
studies
• Utility of imaging and electrophysiology modalities in ocular
models
• Challenges associated with implementing in vivo functional
readouts
Simon Kaja, Chief Scientific Officer, Experimentica Ltd
11.40 Application of artificial intelligence in drug discovery
• Specific applications of predictive algorithms in drug
research
• How “predictions” translate into testable hypotheses and
viable drug candidates
• The future of artificial intelligence-driven drug discovery in
ophthalmology
Andrew A. Radin, CEO & Co-Founder, twoXAR
12.20 Networking Lunch
REGULATORY CHALLENGES IN OPHTHALMIC DRUG DEVELOPMENT
13.30 Regulatory considerations for clinical aspects of ocular drug
development – established and surrogate end-points
• Overview of regulatory requirements for clinical approval of
ophthalmic drugs
• Trends in clinical trial efficacy end-points
• Regulatory view on use of biomarkers and surrogate end-
points in marketing authorisation submissions
• Considerations for rare diseases – conditional marketing
authorisations and exceptional circumstances
Dr Peter Morgan Warren, Medical Assessor, MHRA
KEYNOTE ADDRESS:
14.10 Global reimbursement strategies in ophthalmic clinical
development
• Introduction to global payer requirements
• HTA Core Model
• Use of patient reported outcomes in ophthalmic clinical
trials
• Structuring clinical development plans to meet payer
requirements
David Silverman, Senior Clinical Director,
Ophthalmology, Roche
14.50 Afternoon Tea
15.20 The challenge of replicating clinical trial performance of
intravitreal therapies in the ophthalmology clinic
• Review the development of practice in treatment of
diabetic macular oedema
• The challenges of accepting innovation into everyday
practice
• The emergence of “Real-World” data collection and lessons
learned
• A look into the future
Philip Ashman, Senior Vice President, Managing Director
Europe, Alimera Sciences
16.00 Natural history of disease studies in rare diseases
• The value of running Natural History of Disease studies,
especially in rare diseases
• Why run Natural History of Disease studies?
• Regulatory aspects of running Natural History of Disease
studies
• Natural History of Disease studies as part of running
Innovative trial designs
Aniz Girach, Chief Medical Officer, Nightstar Therapeutics
16.40 Chairman’s Closing Remarks and Close of Day Two
Ophthalmic Drugs
www.ophthalmicdrugs.com Day Two | Tuesday 27th November 2018
Official Media Partners:
Supporters:
Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
MARKETING PARTNERSHIP OPPORTUNITIES
SMi Group is offering companies the opportunity to partner on our dedicated events in order to help raise your company profile,
add value, create awareness of your products/services to our key audience within the pharmaceutical industry. Interested in partnering?
Contact Pav Solanki, Marketing Manager on +44 (0) 207 827 6048 or email: psolanki@smi-online.co.uk
We are proud to be partners with:
SEPTEMBER 2018
Immuno-Oncology
26th – 27th September 2018, London, UK
Biosimilars And Biobetters
26th - 27th September 2018, London, UK
OCTOBER 2018
Cell & Gene Therapy
10th - 11th October 2018, London, UK
Orphan Drugs
17th - 18th October 2018, London, UK
NOVEMBER 2018
Superbugs & Superdrugs USA
12th - 13th November 2018, New Jersey, USA
Biosimilars North America
14th - 15th November 2018, New Jersey, USA
Lyophilization USA
15th - 16th November 2018, New Jersey, USA
Ophthalmic Drugs
26th - 27th November 2018, London, UK
DECEMBER 2018
Cold Chain Distribution
10th - 11th December 2018, London, UK
SMi PHARMACEUTICAL EVENT PLANNER 2018

4. Practical Applications of Artificial
Intelligence in Drug Discovery, Development
and Clinical Trials
Workshop Leader:
Andrew Radin, CEO, twoXAR
Workshop Overview:
Considering the significant interest in artificial intelligence
(AI), this workshop will cover some of the basic underlying
concepts of what AI is, what it isn’t, and how it’s being
applied in drug development.
Why should you attend this workshop:
• Close the gap between the hype and practical
applications of AI
• Understand the conceptual basics of AI to have
productive conversations internally and with partners
• Consider an alternate approach to traditional
biopharmaceutical methods
Agenda:
08.30 Registration Coffee
9.00 Workshop leader introduction
9.10 What is artificial intelligence?
• Defining artificial intelligence
• The “black box”
• Basics and how artificial intelligence works
9.50 Misconceptions surrounding artificial intelligence
• General vs narrow artificial intelligence
• What is the hype all about?
• Constant evolution of artificial intelligence
10.40 Morning Coffee and Networking Break
11.10 Examples of everyday application of artificial
intelligence
• How are you applying artificial intelligence?
• How are other companies applying artificial
intelligence?
• Looking ahead: Future applications of artificial
intelligence
11.50 Examples of application of AI in biopharma
• Current applications of artificial intelligence in
the biopharmaceutical industry
• Methods vs output
• Potential future applications
12.30 Close of workshop
About the Workshop Leader:
Andrew Radin
Andrew A. Radin is Cofounder and Chief Executive Officer
of twoXAR, a company dedicated to transforming how
large biological datasets are harnessed to accelerate the
identification and validation of new medicines. Andrew
developed the company’s proprietary algorithm and
leads product development. Prior to co-founding twoXAR,
Andrew held Chief Technology Officer roles at several
early stage companies where he managed teams as
large as a hundred technologists distributed around the
world. Andrew studied biomedical informatics in Stanford
University’s SCPD graduate program and holds Master of
Science and Bachelor of Science degrees in computer
science from Rochester Institute of Technology.
About the Organisation:
twoXAR is an artificial intelligence-
driven biopharmaceutical company.
The company leverages its computa-
tional platform to identify promising drug candidates,
de-risks the opportunities through preclinical studies, and
progresses drug candidates to the clinic through industry
partnerships. Based in Palo Alto, California, the twoXAR
team includes experts in drug discovery and development,
biomedical informatics, computational biology, data
science and software development.
HALF-DAY POST-CONFERENCE WORKSHOP A
Wednesday 28th November 2018
Copthorne Tara Hotel, Central London, UK
08.30 – 12.30

5. HALF-DAY POST-CONFERENCE WORKSHOP B
Wednesday 28th November 2018
Copthorne Tara Hotel, Central London, UK
13.30 – 16.50
Are Eye Drops the Best Route
for Ophthalmic Therapy?
Workshop Leaders:
Sunil Shah, Professor, Aston University
Afzal Mohamed, Professor, Aston University
Workshop Overview:
Eye drops have long been the mainstay of ophthalmic drug
delivery. Yet they cause ocular surface problems and often
traverse the cornea poorly with little reaching the posterior
segment. Is there anything we can do about this? The aim
of any therapy would be to have good compliance and
effective and easy drug delivery.
This workshop allows an in-depth view in to the different
technologies that are available to either effect improved
results from topical therapy (be it drops, gels or ointments)
and also the limitations and uses of both externally and
internally implantable drug delivery devices.
Why should you attend this workshop:
The workshop will allow you to gain a full understanding of
the technology available at present and its limitations.
Agenda:
13.00 Registration Coffee
13.30 Workshop leader introduction
13.40 Nanotechnology
14.20 Liposomes and other drop related delivery
devices e.g. iontophoresis
15.00 Afternoon Tea
15.30 Externally implantable devices
16.10 Internally implantable devices
16.50 Close of workshop
About the Workshop Leaders:
Sunil Shah qualified from St. Georges Hospital Medical
School and completed his post-graduate training in
Torquay, Exeter, Manchester and Nottingham. He has
been a Consultant at the Birmingham and Midland Eye
Centre since 2000 where he runs a cornea and cataract
service. Professor Shah is a Section Editor for the British
Journal of Ophthalmology and a reviewer for Eye,
American Journal of Ophthalmology, Ophthalmology,
Investigative Ophthalmology and Visual Sciences, Contact
Lens and Anterior Eye, Journal of Cataract and Refractive
Surgery and Journal of Refractive Surgery. He is also an
honorary Professor at the University of Ulster, a Professor at
Aston University and an honorary Professor at UKM Medical
Centre, Malaysia. Professor Shah also provides specialist
advice to NICE and is a representative for the Royal College
of Ophthalmologists to the British Standards Institute. He is
the Principle Editor and E Tutor for the E-learning course in
Refractive surgery for the University of Ulster. He represents
the Royal College of Ophthalmologists on its refractive
sub-committee and its academic committee and he is a
past President of the British Society for Refractive Surgery
and a past council member for the British Contact Lens
Association.
Afzal Mohammed is Professor of Pharmaceutics and Head
of Pharmaceutics at Aston University. He is an internationally
leading scientist and a key opinion leader in paediatric
formulation development. The translational interface of his
research is funded by grants from various bodies including
MRC, EPSRC, BBSRC and NC3R as well as funding from
various international pharmaceutical companies and
INNOVATE UK. He has presented his research findings at
major national and international conferences and was
awarded Fellowship of the Academy of Pharmaceutical
Sciences in 2017. Research from his group has led to a
total of 102 publications which include research articles,
review papers, journal editorials, book chapters, PhD
theses, published conference proceedings and patent
applications as well as over 80 abstracts at various national
and international conferences. Afzal serves as an Associate
Editor for the Journal of Pharmaceutics as well as BMC
Journal of Pharmacology and Toxicology and is on the
editorial board for four other journals including Nature
Scientific Reports. Afzal Mohammed is the lead inventor
of a patented novel dry particle coating technology (WO
2016/066462 A1). He set up Aston Particle Technologies Ltd
(www.astonparticletechnologies.com) in July 2016 to unlock
the commercial potential for the technology.

6. OPHTHALMIC DRUGS
Conference: Monday 26th Tuesday 27th November 2018, Copthorne Tara Hotel, London, UK
Workshops: Wednesday 28th November 2018, Copthorne Tara Hotel, London, UK
4 WAYS TO REGISTER
ONLINE at www.ophthalmicdrugs.com
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd,
Ground First Floor, 1 Westminster Bridge Road London, SE1 7XW, UK
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk
EARLY BIRD
DISCOUNT
□ Book by 29th June to receive £300 off the conference price
□ Book by 28th September to receive £200 off the conference price
□ Book by 31st October to receive £100 off the conference price
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-270 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
SMi Group will apply surcharges to commercial cards
Please tick here □ if the card provided is not a commercial card
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
Card Billing Address (If different from above):
PAYMENT
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged
on Document portal and literature distribution for all UK customers and for those EU
Customers not supplying a registration number for their own country here.
______________________________________________________________________________________
VAT
I cannot attend but would like to purchase access to the following
Document Portal/paper copy documentation Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
DOCUMENTATION
CONFERENCE PRICES
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference 2 Workshops £2697.00 + VAT £3236.40
□ Conference 1 Workshop A □ B □ £2098.00 + VAT £2517.60
□ Conference only £1499.00 + VAT £1798.80
□ 2 Workshops £1198.00 + VAT £1437.60
□ 1 Workshop only A □ B □ £599.00 + VAT £718.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to
the Document Portal. Presentations that are available for download will be subject to
distribution rights by speakers. Please note that some presentations may not be available
for download. Access information for the document portal will be sent to the e-mail
address provided during registration. Details are sent within 24 hours post conference.
Unique Reference Number
Our Reference LVP-270
DELEGATE DETAILS
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
If you would like to continue to receive email updates about
our events, please tick □
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
DELEGATE DETAILS
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given
until payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send
a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of
the event. Regretfully cancellation after this time cannot be accepted. We will however provide
the conferences documentation via the Document Portal to any delegate who has paid but is
unable to attend for any reason. Due to the interactive nature of the Briefings we are not normally
able to provide documentation in these circumstances. We cannot accept cancellations of
orders placed for Documentation or the Document Portal as these are reproduced specifically to
order. If we have to cancel the event for any reason, then we will make a full refund immediately,
but disclaim any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Privacy policy / Opt Out: For full details on our privacy policyplease go to
http://smi-online.co.uk/privacy-legals/privacy-policy. If you no longer wish to receive email
updates you can opt out by going to the following webpage http://smi-online.co.uk/opt-out
Terms and Conditions of Booking
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712
VENUE Copthorne Tara Hotel, Scarsdale Place, Kensington, London W8 5SY